Dr. Chen joined the Cancer Therapy Evaluation Program of the National Cancer Institute (NCI) in 2000. She currently serves as associate chief of the Investigational Drug Branch Section III, which focuses on the clinical development of antibody-based therapeutics, active immunotherapies, MAPK and RTK inhibitors as well as antiangiogenic agents. She has been closely involved in the NCI’s efforts on novel agent combinations and is a member of the NCI Experimental Therapeutics Committee.
Dr. Chen graduated from the Shanghai First Medical College of the Fudan University in China. She is board-certified in medical oncology after completing the Fellowship training at Georgetown University Medical Center.
She is on the organizing committee of the International Symposium of Anti-angiogenesis Therapy, the scientific committees for the EORTC-AACR-NCI Annual Meeting on Molecular Targeted Therapy, the ASCO-NCI-EORTC Annual Biomarkers Symposium, and the Biotherapy Development Association.
Dr. Chen has been an invited speaker at national and international meetings on cancer drug development strategies, and is the first or coauthor of more than 50 original and review papers in peer-reviewed journals including the Journal of Clinical Oncology, Nature Reviews, and the New England Journal of Medicine.